Metraipolis › archive › dc_e449138c355f
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer — Europe PMC PMID:41294658
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41294658
- DOI
- 10.3390/curroncol32110596
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T02:00:50.922Z
- SHA-256 of the archived text
68903039cf1cb075b1700ebc83ddbf004e61503b5cd17fd8a9abd9b0e6681b7f- Stable URL of this page
https://metraipolis.com/documento/dc_e449138c355f
How to cite
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer — Europe PMC PMID:41294658 — Europe PMC (en), https://europepmc.org/article/MED/41294658 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e449138c355f (Metraipolis archive dc_e449138c355f, sha256 68903039cf1cb075b1700ebc83ddbf004e61503b5cd17fd8a9abd9b0e6681b7f)
BibTeX
@misc{dce449138c355f,
title = {Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer — Europe PMC PMID:41294658},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41294658},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e449138c355f; sha256 68903039cf1cb075b1700ebc83ddbf004e61503b5cd17fd8a9abd9b0e6681b7f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41294658. Agents can read the archived copy with the MCP tool read_document.